ticlopidine has been researched along with Hypertension in 75 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 9.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 7.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| " The associated SNPs studied may be useful to predict clopidogrel resistance in Chinese patients with ischemic stroke." | 7.83 | Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. ( Cai, YF; Chen, XM; Chen, YB; Huang, M; Jin, J; Li, JL; Liu, R; Yu, WB; Zhao, M; Zhao, YQ; Zhou, ZY, 2016) |
| "This study tested the hypothesis that P2Y12 receptor blockade with clopidogrel preserves renal autoregulatory ability during ANG II-induced hypertension." | 7.80 | Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension. ( De Miguel, C; Inscho, EW; Osmond, DA; Pollock, JS; Yamamoto, T; Zhang, S, 2014) |
| "Using a mouse model of angiotensin II (Ang II) infusion (1,500 ng/[kg·min] for 7 days), we determined the role of platelet activation in Ang II infusion-induced cardiac inflammation and fibrosis using a P2Y12 receptor inhibitor, clopidogrel (50 mg/[kg·day])." | 7.79 | Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. ( Cui, W; Du, J; Jia, LX; Li, TT; Liu, O; Qi, GM; Qi, YF; Yang, M; Zhang, WM, 2013) |
| "There is an increased risk of troublesome epistaxis in patients taking aspirin or clopidogrel." | 7.75 | Clopidogrel versus low-dose aspirin as risk factors for epistaxis. ( Molony, NC; Rainsbury, JW, 2009) |
| "Agranulocytosis is a rare complication of ticlopidine and can be life-threatening." | 7.74 | Necrotizing gingivitis: a possible oral manifestation of ticlopidine-induced agranulocytosis. ( Fun, LC; Karim, F; Rahman, RA; Rajandram, RK; Ramli, R, 2007) |
| " Finally, the chronic administration of C plus T for twelve months induced a further improvement of all considered parameters." | 6.68 | Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. ( Abrignani, MG; Caruso, R; Geraci, AM; Longo, B; Novo, S; Pavone, G; Pernice, C; Strano, A; Zamueli, M, 1996) |
| "Aspirin resistance was detected in 22 (16." | 5.40 | Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. ( Akturk, IF; Caglar, FN; Caglar, IM; Erturk, M; Surgit, O; Tuncer, N; Uzun, F; Yalcın, AA, 2014) |
| "The EUCLID trial investigated the effect of monotherapy with ticagrelor versus clopidogrel in 13,885 patients with peripheral artery disease (PAD); the primary endpoint was cardiovascular death, myocardial infarction, or ischaemic stroke." | 5.27 | Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. ( Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM, 2018) |
| "We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension." | 5.16 | Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. ( Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 5.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| " Three preventive strategies were identified: (i) intra-operative transcranial Doppler (TCD) ultrasound and completion angioscopy which virtually abolished intra-operative stroke, primarily through the removal of residual luminal thrombus prior to restoration of flow; (ii) dual antiplatelet therapy with a single 75-mg dose of clopidogrel the night before surgery in addition to regular 75 mg aspirin which virtually abolished post-operative thromboembolic stroke and may also have contributed towards a decline in stroke/death following major cardiac events; and (iii) the provision of written guidance for managing post-CEA hypertension which was associated with virtual abolition of intracranial haemorrhage and stroke as a result of hyperperfusion syndrome." | 4.89 | Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy. ( Bell, PR; Bown, MJ; Dennis, MJ; London, NJ; McCarthy, MJ; Nasim, A; Naylor, AR; Sayers, RD, 2013) |
| "Long-term use of aspirin and severity of cerebral infarction are risk factors for gastrointestinal bleeding in cerebral infarction patients receiving dual antiplatelet therapy." | 4.31 | Risk factors for gastrointestinal bleeding in patients with cerebral infarction after dual antiplatelet therapy. ( Huang, J; Liao, F; Shu, X; Tang, J, 2023) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 3.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| " The associated SNPs studied may be useful to predict clopidogrel resistance in Chinese patients with ischemic stroke." | 3.83 | Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. ( Cai, YF; Chen, XM; Chen, YB; Huang, M; Jin, J; Li, JL; Liu, R; Yu, WB; Zhao, M; Zhao, YQ; Zhou, ZY, 2016) |
| "A 62-year-old woman with hypertension, type 2 diabetes mellitus, hyperlipemia and coronary heart disease started taking clopidogrel, with no addition of any other new drugs." | 3.80 | Acquired pure red cell aplasia due to treatment with clopidogrel: first case report. ( Li, G; Li, ZQ; Yang, JD; Yang, QY, 2014) |
| "This study tested the hypothesis that P2Y12 receptor blockade with clopidogrel preserves renal autoregulatory ability during ANG II-induced hypertension." | 3.80 | Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension. ( De Miguel, C; Inscho, EW; Osmond, DA; Pollock, JS; Yamamoto, T; Zhang, S, 2014) |
| "Using a mouse model of angiotensin II (Ang II) infusion (1,500 ng/[kg·min] for 7 days), we determined the role of platelet activation in Ang II infusion-induced cardiac inflammation and fibrosis using a P2Y12 receptor inhibitor, clopidogrel (50 mg/[kg·day])." | 3.79 | Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. ( Cui, W; Du, J; Jia, LX; Li, TT; Liu, O; Qi, GM; Qi, YF; Yang, M; Zhang, WM, 2013) |
| " Preoperative treatment with clopidogrel, particularly when it is continued to the day before surgery, and postoperative arterial hypertension seem to be associated with a higher risk of neck bleeding after CEA, requiring re-exploration in most cases." | 3.77 | Predictors of neck bleeding after eversion carotid endarterectomy. ( Ballotta, E; Baracchini, C; Gruppo, M; Lorenzetti, R; Mazzalai, F; Meneghetti, G, 2011) |
| "We report a 56-year-old patient who had been taking antihypertensive medication in combination with prophylactic aspirin for 19 years who was diagnosed with stable angina with significant coronary artery stenosis on angiography." | 3.75 | Spontaneous spinal epidural hematoma: an urgent complication of adding clopidogrel to aspirin therapy. ( Chung, HS; Kim, JH; Kwon, TH; Moon, HJ; Park, YK, 2009) |
| "There is an increased risk of troublesome epistaxis in patients taking aspirin or clopidogrel." | 3.75 | Clopidogrel versus low-dose aspirin as risk factors for epistaxis. ( Molony, NC; Rainsbury, JW, 2009) |
| "Agranulocytosis is a rare complication of ticlopidine and can be life-threatening." | 3.74 | Necrotizing gingivitis: a possible oral manifestation of ticlopidine-induced agranulocytosis. ( Fun, LC; Karim, F; Rahman, RA; Rajandram, RK; Ramli, R, 2007) |
| "A 73-year-old female treated with clopidogrel for vascular disease presented with sudden onset of back pain, urinary retention and paraplegia." | 3.73 | Nontraumatic spinal epidural hematoma associated with clopidogrel. ( Das, K; Karabatsou, K; Rainov, NG; Sinha, A, 2006) |
| "Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke." | 3.70 | Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000) |
| "(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000) |
| "Most retinal or subretinal hemorrhages in eyes enrolled in CATT were less than 1 DA." | 2.82 | Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. ( Ahmed, O; Daniel, E; Grunwald, JE; Maguire, MG; Martin, DF; Ying, GS, 2016) |
| " Finally, the chronic administration of C plus T for twelve months induced a further improvement of all considered parameters." | 2.68 | Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. ( Abrignani, MG; Caruso, R; Geraci, AM; Longo, B; Novo, S; Pavone, G; Pernice, C; Strano, A; Zamueli, M, 1996) |
| "Hypertension was seen in 55% of all occlusions, hyperlipaemia in 33%, and diabetes in 29%." | 2.65 | The influence of ticlopidine on the natural course of retinal vein occlusion. ( Baarsma, GS; Henkes, HE; Houtsmuller, AJ; Klompe, M; Tijssen, J; Vermeulen, JA; Zahn, KJ, 1984) |
| "We report a case of multiple coronary thrombosis involving the left anterior descending artery and circumflex artery and stent implantation to the subtotally stenotic right renal artery in a women with unstable angina pectoris, essential thrombocytosis and previous history of renal artery trombosis." | 2.43 | Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. ( Bugra, Z; Ekmekci, A; Meric, M; Ozben, B; Umman, S, 2006) |
| "Stroke is a major cause of morbidity and mortality." | 2.41 | A benefit-risk assessment of agents used in the secondary prevention of stroke. ( MacWalter, RS; Shirley, CP, 2002) |
| "Aspirin resistance was detected in 22 (16." | 1.40 | Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. ( Akturk, IF; Caglar, FN; Caglar, IM; Erturk, M; Surgit, O; Tuncer, N; Uzun, F; Yalcın, AA, 2014) |
| "Pretreatment with cilostazol (100 mg/kg) significantly reduced infarct size." | 1.36 | Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. ( Hashimoto, A; Ito, H; Matsumoto, Y; Miyakoda, G; Yao, H, 2010) |
| "Essential hypertension is associated with increased risk of arterial thrombotic disease." | 1.36 | Platelet activation in essential hypertension: implications for antiplatelet treatment. ( Douma, S; Ferro, A; Gkaliagkousi, E; Passacquale, G; Zamboulis, C, 2010) |
| "We report a patient who presented with transient ischemic attack (TIA) associated with stenosis of the accessory MCA ostium." | 1.35 | Transient ischemic attack associated with stenosis of accessory middle cerebral artery: a case report. ( Gao, F; Jiang, WJ, 2009) |
| "We present a patient with type 2 diabetes mellitus, arterial hypertension and hyperlipidaemia, who had simultaneous oculomotor and trochlear nerve palsies." | 1.33 | Simultaneous, painless, homolateral oculomotor and trochlear nerve palsies in a patient with type 2 diabetes mellitus. Neuropathy or brainstem infarction? ( Heliopoulos, I; Maltezos, E; Papanas, N; Piperidou, H, 2006) |
| "Ticlopidine hydrochloride was administered at a dose of 200 mg daily for 4 weeks." | 1.31 | Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis. ( Akai, Y; Ando, Y; Asano, Y; Furuya, H; Inoue, M; Kusano, E; Tabei, K, 2002) |
| "He had high fever and convulsive seizures after admission." | 1.30 | A case of dermatomyositis complicated by thrombotic thrombocytopenic purpura. ( Arase, S; Horie, T; Miyaoka, Y; Nameda, Y; Sano, N; Shigekiyo, T; Urano, Y, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.33) | 18.7374 |
| 1990's | 5 (6.67) | 18.2507 |
| 2000's | 29 (38.67) | 29.6817 |
| 2010's | 39 (52.00) | 24.3611 |
| 2020's | 1 (1.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J | 1 |
| Liao, F | 1 |
| Tang, J | 1 |
| Shu, X | 1 |
| Su, J | 1 |
| Yu, Q | 1 |
| Zhu, H | 1 |
| Li, X | 1 |
| Cui, H | 1 |
| Du, W | 1 |
| Ji, L | 1 |
| Tong, M | 1 |
| Zheng, Y | 1 |
| Xu, H | 1 |
| Zhang, J | 1 |
| Zhu, Y | 1 |
| Xia, Y | 1 |
| Liu, T | 1 |
| Yao, Q | 1 |
| Yang, J | 1 |
| Chen, X | 2 |
| Yu, J | 1 |
| Zhong, Z | 1 |
| Hou, J | 1 |
| Zhang, Q | 1 |
| Li, B | 1 |
| Li, C | 1 |
| Liu, Z | 1 |
| Yang, M | 2 |
| Zhong, W | 1 |
| He, X | 1 |
| Wu, H | 2 |
| Zhong, M | 1 |
| Zhao, P | 1 |
| Norgren, L | 1 |
| Patel, MR | 1 |
| Hiatt, WR | 1 |
| Wojdyla, DM | 1 |
| Fowkes, FGR | 1 |
| Baumgartner, I | 1 |
| Mahaffey, KW | 2 |
| Berger, JS | 1 |
| Jones, WS | 1 |
| Katona, BG | 1 |
| Held, P | 1 |
| Blomster, JI | 1 |
| Rockhold, FW | 1 |
| Björck, M | 1 |
| Akturk, IF | 1 |
| Caglar, FN | 1 |
| Erturk, M | 1 |
| Tuncer, N | 1 |
| Yalcın, AA | 1 |
| Surgit, O | 1 |
| Uzun, F | 1 |
| Caglar, IM | 1 |
| Naylor, AR | 1 |
| Sayers, RD | 1 |
| McCarthy, MJ | 1 |
| Bown, MJ | 1 |
| Nasim, A | 1 |
| Dennis, MJ | 1 |
| London, NJ | 1 |
| Bell, PR | 1 |
| Jia, LX | 1 |
| Qi, GM | 1 |
| Liu, O | 1 |
| Li, TT | 1 |
| Cui, W | 1 |
| Zhang, WM | 1 |
| Qi, YF | 1 |
| Du, J | 2 |
| Du, XJ | 1 |
| Kiriazis, H | 1 |
| Li, G | 1 |
| Li, ZQ | 1 |
| Yang, QY | 1 |
| Yang, JD | 1 |
| Osmond, DA | 3 |
| Zhang, S | 2 |
| Pollock, JS | 1 |
| Yamamoto, T | 1 |
| De Miguel, C | 1 |
| Inscho, EW | 3 |
| Opie, LH | 1 |
| Giachini, FR | 2 |
| Leite, R | 1 |
| Lima, VV | 2 |
| Webb, RC | 2 |
| Tostes, RC | 2 |
| Lakshmanan, M | 1 |
| Daels, FP | 1 |
| Gaizauskas, A | 1 |
| Rioja, J | 1 |
| Varshney, AK | 1 |
| Erkan, E | 1 |
| Ozgok, Y | 1 |
| Melekos, M | 1 |
| de la Rosette, JJ | 1 |
| Silber, T | 1 |
| Ziemann, U | 1 |
| Ernemann, U | 1 |
| Bischof, F | 1 |
| Ying, GS | 1 |
| Maguire, MG | 1 |
| Daniel, E | 1 |
| Grunwald, JE | 1 |
| Ahmed, O | 1 |
| Martin, DF | 1 |
| Spence, JD | 1 |
| Rayner, BL | 1 |
| Odden, MC | 1 |
| McClure, LA | 3 |
| Sawaya, BP | 1 |
| White, CL | 3 |
| Peralta, CA | 1 |
| Field, TS | 1 |
| Hart, RG | 3 |
| Benavente, OR | 3 |
| Pergola, PE | 2 |
| Liu, R | 1 |
| Zhou, ZY | 1 |
| Chen, YB | 1 |
| Li, JL | 1 |
| Yu, WB | 1 |
| Chen, XM | 1 |
| Zhao, M | 1 |
| Zhao, YQ | 1 |
| Cai, YF | 1 |
| Jin, J | 1 |
| Huang, M | 1 |
| Buck, J | 1 |
| Kaboli, P | 1 |
| Gage, BF | 1 |
| Cram, P | 1 |
| Vaughan Sarrazin, MS | 1 |
| Kowalski, R | 1 |
| Dropiński, J | 1 |
| Brzostek, T | 1 |
| Szot, P | 1 |
| Rzeszutko, M | 1 |
| Kasper, M | 1 |
| Sawicka, A | 1 |
| Szczeklik, A | 1 |
| Gao, F | 1 |
| Jiang, WJ | 1 |
| Motovska, Z | 1 |
| Widimsky, P | 1 |
| Petr, R | 1 |
| Bilkova, D | 1 |
| Marinov, I | 1 |
| Simek, S | 1 |
| Kala, P | 1 |
| Stulman, J | 1 |
| McGinn, T | 1 |
| Korenstein, D | 1 |
| Rainsbury, JW | 1 |
| Molony, NC | 1 |
| Moon, HJ | 1 |
| Kim, JH | 2 |
| Kwon, TH | 1 |
| Chung, HS | 1 |
| Park, YK | 1 |
| Ito, H | 1 |
| Hashimoto, A | 1 |
| Matsumoto, Y | 1 |
| Yao, H | 1 |
| Miyakoda, G | 1 |
| Carneiro, FS | 1 |
| Zeng, C | 1 |
| Karkos, CD | 1 |
| Karamanos, DG | 1 |
| Papazoglou, KO | 1 |
| Demiropoulos, FP | 1 |
| Papadimitriou, DN | 1 |
| Gerassimidis, TS | 1 |
| Gkaliagkousi, E | 1 |
| Passacquale, G | 1 |
| Douma, S | 1 |
| Zamboulis, C | 1 |
| Ferro, A | 1 |
| Coppola, A | 1 |
| De Simone, C | 1 |
| Di Capua, M | 1 |
| Tufano, A | 1 |
| Cimino, E | 1 |
| Conca, P | 1 |
| Guida, A | 1 |
| Morisco, C | 1 |
| Di Minno, G | 1 |
| Pearce, L | 1 |
| Pergola, P | 1 |
| Roldan, A | 2 |
| Benavente, MF | 2 |
| Coffey, C | 1 |
| Szychowski, JM | 2 |
| Conwit, R | 2 |
| Heberling, PA | 1 |
| Howard, G | 1 |
| Bazan, C | 1 |
| Vidal-Pergola, G | 1 |
| Talbert, R | 1 |
| Khan, M | 1 |
| Kamal, AK | 1 |
| Baracchini, C | 1 |
| Gruppo, M | 1 |
| Mazzalai, F | 1 |
| Lorenzetti, R | 1 |
| Meneghetti, G | 1 |
| Ballotta, E | 1 |
| Awad, HH | 1 |
| Zubaid, M | 1 |
| Alsheikh-Ali, AA | 1 |
| Al Suwaidi, J | 1 |
| Anderson, FA | 1 |
| Gore, JM | 1 |
| Goldberg, RJ | 1 |
| De Servi, S | 1 |
| Navarese, EP | 1 |
| D'Urbano, M | 1 |
| Savonitto, S | 1 |
| Lip, GY | 2 |
| Felmeden, DC | 2 |
| Dwivedi, G | 1 |
| Mazya, M | 1 |
| Egido, JA | 1 |
| Ford, GA | 1 |
| Lees, KR | 1 |
| Mikulik, R | 1 |
| Toni, D | 1 |
| Wahlgren, N | 1 |
| Ahmed, N | 1 |
| Pugi, A | 1 |
| Borrone, G | 1 |
| Moschini, M | 1 |
| Lapi, F | 1 |
| Mugelli, A | 1 |
| Vannacci, A | 1 |
| Pretell, EJ | 1 |
| Del Brutto, OH | 1 |
| Kase, CS | 1 |
| Arauz, A | 1 |
| Meyer, BC | 1 |
| Meissner, I | 1 |
| Demaerschalk, BM | 1 |
| Coffey, CS | 1 |
| Pearce, LA | 1 |
| Irby, LH | 1 |
| Peri, K | 1 |
| Hess, CN | 1 |
| Broderick, S | 1 |
| Piccini, JP | 1 |
| Alexander, KP | 1 |
| Newby, LK | 1 |
| Shaw, LK | 1 |
| Alexander, JH | 1 |
| Peterson, ED | 1 |
| Granger, CB | 1 |
| Lopes, RD | 1 |
| Miao, Z | 1 |
| Jiang, L | 1 |
| Bao, Y | 1 |
| Jiao, L | 1 |
| Li, S | 1 |
| Wu, J | 1 |
| Hua, Y | 1 |
| Li, Y | 1 |
| Zhu, J | 1 |
| Zhu, F | 1 |
| Liu, X | 1 |
| Ling, F | 1 |
| Fihn, SD | 1 |
| Gardin, JM | 1 |
| Abrams, J | 1 |
| Berra, K | 1 |
| Blankenship, JC | 1 |
| Dallas, AP | 1 |
| Douglas, PS | 1 |
| Foody, JM | 1 |
| Gerber, TC | 1 |
| Hinderliter, AL | 1 |
| King, SB | 1 |
| Kligfield, PD | 1 |
| Krumholz, HM | 1 |
| Kwong, RY | 1 |
| Lim, MJ | 1 |
| Linderbaum, JA | 1 |
| Mack, MJ | 1 |
| Munger, MA | 1 |
| Prager, RL | 1 |
| Sabik, JF | 1 |
| Shaw, LJ | 1 |
| Sikkema, JD | 1 |
| Smith, CR | 1 |
| Smith, SC | 1 |
| Spertus, JA | 1 |
| Williams, SV | 1 |
| Kusano, E | 1 |
| Inoue, M | 1 |
| Akai, Y | 1 |
| Furuya, H | 1 |
| Ando, Y | 1 |
| Tabei, K | 1 |
| Asano, Y | 1 |
| MacWalter, RS | 1 |
| Shirley, CP | 1 |
| Bauriedel, G | 2 |
| Skowasch, D | 2 |
| Schneider, M | 1 |
| Andrié, R | 1 |
| Jabs, A | 1 |
| Lüderitz, B | 2 |
| Ornato, JP | 1 |
| Georgiadis, D | 1 |
| Michel, P | 1 |
| Bogousslavsky, J | 1 |
| Baumgartner, RW | 1 |
| Malcolm, J | 2 |
| Meggison, H | 1 |
| Sigal, R | 2 |
| Cay, S | 1 |
| Yilmaz, MB | 1 |
| Korkmaz, S | 1 |
| Hacke, W | 1 |
| Arzur, J | 1 |
| De la Gastine, B | 1 |
| Bessodes, A | 1 |
| Coquerel, A | 1 |
| Viktor, A | 1 |
| Schneider-Schmitt, M | 1 |
| Nickenig, G | 1 |
| Papanas, N | 1 |
| Heliopoulos, I | 1 |
| Piperidou, H | 1 |
| Maltezos, E | 1 |
| Ozben, B | 1 |
| Ekmekci, A | 1 |
| Bugra, Z | 1 |
| Umman, S | 1 |
| Meric, M | 1 |
| Arnaout, A | 1 |
| Karabatsou, K | 1 |
| Sinha, A | 1 |
| Das, K | 1 |
| Rainov, NG | 1 |
| Rajandram, RK | 1 |
| Ramli, R | 1 |
| Karim, F | 1 |
| Rahman, RA | 1 |
| Fun, LC | 1 |
| Graciano, ML | 1 |
| Nishiyama, A | 1 |
| Jackson, K | 1 |
| Seth, DM | 1 |
| Ortiz, RM | 1 |
| Prieto-Carrasquero, MC | 1 |
| Kobori, H | 1 |
| Navar, LG | 1 |
| Tu, X | 1 |
| Xie, Y | 1 |
| Shi, S | 1 |
| Wang, J | 1 |
| Chen, Y | 1 |
| Li, J | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Houtsmuller, AJ | 1 |
| Vermeulen, JA | 1 |
| Klompe, M | 1 |
| Zahn, KJ | 1 |
| Henkes, HE | 1 |
| Baarsma, GS | 1 |
| Tijssen, J | 1 |
| Franchimont, D | 1 |
| Frère, P | 1 |
| Lebrun, F | 1 |
| Fassotte, MF | 1 |
| D'Orio, V | 1 |
| Novo, S | 1 |
| Abrignani, MG | 1 |
| Pavone, G | 1 |
| Zamueli, M | 1 |
| Pernice, C | 1 |
| Geraci, AM | 1 |
| Longo, B | 1 |
| Caruso, R | 1 |
| Strano, A | 1 |
| Miyaoka, Y | 1 |
| Urano, Y | 1 |
| Nameda, Y | 1 |
| Shigekiyo, T | 1 |
| Horie, T | 1 |
| Sano, N | 1 |
| Arase, S | 1 |
| Brigot, C | 1 |
| Courillon-Mallet, A | 1 |
| Roucayrol, AM | 1 |
| Cattan, D | 1 |
| Yamada, M | 1 |
| Omata, K | 1 |
| Abe, F | 1 |
| Ito, S | 1 |
| Abe, K | 1 |
| Holroyd-Leduc, JM | 1 |
| Kapral, MK | 1 |
| Austin, PC | 1 |
| Tu, JV | 1 |
| Kim, HS | 1 |
| Waksman, R | 1 |
| Kollum, M | 1 |
| Bhargava, B | 1 |
| Kent, KM | 1 |
| Mintz, GS | 1 |
| Kolodgie, FD | 1 |
| Virmani, R | 1 |
| Horwich, TB | 1 |
| Fonarow, GC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease[NCT01732822] | Phase 3 | 13,885 participants (Actual) | Interventional | 2012-12-04 | Completed | ||
| Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)[NCT00593450] | Phase 3 | 1,208 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| TEC4Home Stroke - Assessing the Feasibility of Home Telemonitoring Technology in Managing Hypertension Among Stroke/TIA Patients. Pilot Study at Vancouver Stroke Program in Collaboration With TEC4Home Heart Failure Team[NCT03712033] | 50 participants (Actual) | Observational | 2018-03-01 | Completed | |||
| Routine Or Selective Stress Testing After Revascularization: ROSSTAR Trial RCT Outline[NCT03067402] | 1,100 participants (Anticipated) | Interventional | 2017-03-20 | Not yet recruiting | |||
| Register of Cardiovascular Complications Among People Living With HIV[NCT02453919] | 800 participants (Anticipated) | Observational [Patient Registry] | 2010-02-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 117 |
| Clopidogrel 75 mg od | 115 |
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 628 |
| Clopidogrel 75 mg od | 635 |
Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 179 |
| Clopidogrel 75 mg od | 208 |
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1211 |
| Clopidogrel 75 mg od | 1250 |
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg bd | 751 |
| Clopidogrel 75 mg od | 740 |
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 766 |
| Clopidogrel 75 mg od | 759 |
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 839 |
| Clopidogrel 75 mg od | 833 |
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 363 |
| Clopidogrel 75 mg od | 343 |
Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1312 |
| Clopidogrel 75 mg od | 1314 |
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 846 |
| Clopidogrel 75 mg od | 892 |
Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 100 |
| Clopidogrel 75 mg od | 116 |
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 349 |
| Clopidogrel 75 mg od | 334 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1119 |
| Clopidogrel 75 mg od | 1140 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1183 |
| Clopidogrel 75 mg od | 1199 |
Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 983 |
| Clopidogrel 75 mg od | 992 |
Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 789 |
| Clopidogrel 75 mg od | 786 |
Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 250 |
| Clopidogrel 75 mg od | 272 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 206 |
| Clopidogrel 75 mg od | 188 |
Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 168 |
| Clopidogrel 75 mg od | 112 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 113 |
| Clopidogrel 75 mg od | 109 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 193 |
| Clopidogrel 75 mg od | 175 |
"Change in ankle brachial index (ABI) / toe brachial index (TBI).~Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):~Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: <0.4~Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:~Normal: >0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: <0.35 and toe pressure 40 mmHg Severe: <0.35 and toe pressure < 30 mmHg" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Change in ABI/TBI (Mean) | |||
|---|---|---|---|---|
| ABI - 6 months N = 6184(Tica), 6319(Clopi) | ABI - End of treatment N = 4951(Tica), 5073(Clopi) | TBI - 6 months N = 55(Tica), 48(Clopi) | TBI - End of treatment N = 36(Tica), 21(Clopi) | |
| Clopidogrel 75 mg od | 0.011 | 0.016 | 0.036 | -0.065 |
| Ticagrelor 90 mg bd | 0.016 | 0.022 | 0.050 | 0.059 |
"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.~Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | |||||
|---|---|---|---|---|---|---|
| Stage I - End of treatment | Stage IIa - End of treatment | Stage IIb - End of treatment | Stage III - End of treatment | Stage IV - End of treatment | Missing - End of treatment | |
| Clopidogrel - Stage I | 743 | 230 | 56 | 9 | 4 | 250 |
| Clopidogrel - Stage IIa | 723 | 1956 | 311 | 15 | 7 | 724 |
| Clopidogrel - Stage IIb | 198 | 557 | 450 | 23 | 10 | 370 |
| Clopidogrel - Stage III | 33 | 33 | 38 | 23 | 5 | 60 |
| Clopidogrel - Stage IV | 19 | 21 | 15 | 12 | 13 | 45 |
| Ticagrelor - Stage I | 775 | 227 | 45 | 7 | 7 | 248 |
| Ticagrelor - Stage IIa | 683 | 1948 | 269 | 24 | 7 | 743 |
| Ticagrelor - Stage IIb | 171 | 560 | 469 | 12 | 5 | 403 |
| Ticagrelor - Stage III | 15 | 41 | 39 | 31 | 1 | 59 |
| Ticagrelor - Stage IV | 26 | 28 | 19 | 7 | 13 | 47 |
"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.~Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.~Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Category 0 - End of treatment | Category 1/2 - End of treatment | Category 3 - End of treatment | Category 4 - End of treatment | Category 5 - End of treatment | Category 6 - End of treatment | Missing - End of treatment | |
| Clopidogrel - Cat 0 | 743 | 230 | 56 | 9 | 2 | 2 | 250 |
| Clopidogrel - Cat 1/2 | 723 | 1956 | 311 | 15 | 6 | 1 | 724 |
| Clopidogrel - Cat 3 | 198 | 557 | 450 | 23 | 6 | 4 | 370 |
| Clopidogrel - Cat 4 | 33 | 33 | 38 | 23 | 4 | 1 | 60 |
| Clopidogrel - Cat 5 | 13 | 18 | 12 | 11 | 12 | 0 | 34 |
| Clopidogrel - Cat 6 | 6 | 3 | 3 | 1 | 1 | 0 | 11 |
| Ticagrelor - Cat 0 | 775 | 227 | 45 | 7 | 5 | 2 | 248 |
| Ticagrelor - Cat 3 | 171 | 560 | 469 | 12 | 3 | 2 | 403 |
| Ticagrelor - Cat 4 | 15 | 41 | 39 | 31 | 1 | 0 | 59 |
| Ticagrelor - Cat 5 | 23 | 23 | 13 | 4 | 11 | 0 | 33 |
| Ticagrelor - Cat 6 | 3 | 5 | 6 | 3 | 0 | 2 | 14 |
| Ticagrelor - Stage II | 683 | 1948 | 269 | 24 | 4 | 3 | 743 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | mm^2 (Mean) |
|---|---|
| 1-Lucentis Monthly | 6.6 |
| 2-Avastin Monthly | 6.5 |
| 3-Lucentis as Needed | 7.3 |
| 4-Avastin as Needed | 7.0 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | mm^2 (Mean) |
|---|---|
| 1-Lucentis Monthly | -0.1 |
| 2-Avastin Monthly | 0.3 |
| 3-Lucentis as Needed | 0.6 |
| 4-Avastin as Needed | 1.3 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | US dollars per patient (Mean) |
|---|---|
| 1-Lucentis Monthly | 23400 |
| 2-Avastin Monthly | 595 |
| 3-Lucentis as Needed | 13800 |
| 4-Avastin as Needed | 385 |
"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.~In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement." (NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | No. of Letters (Mean) |
|---|---|
| 1-Lucentis Monthly | 8.5 |
| 2-Avastin Monthly | 8.0 |
| 3-Lucentis as Needed | 6.8 |
| 4-Avastin as Needed | 5.9 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | mm Hg (Mean) |
|---|---|
| 1-Lucentis Monthly | -0.9 |
| 2-Avastin Monthly | -1.4 |
| 3-Lucentis as Needed | -1.9 |
| 4-Avastin as Needed | -2.1 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | mm Hg (Mean) |
|---|---|
| 1-Lucentis Monthly | -2.1 |
| 2-Avastin Monthly | -5.4 |
| 3-Lucentis as Needed | -5.2 |
| 4-Avastin as Needed | -4.5 |
Cumulative over the 1 year of trial (NCT00593450)
Timeframe: 1 Year
| Intervention | Number of Treatments (Mean) |
|---|---|
| 1-Lucentis Monthly | 11.7 |
| 2-Avastin Monthly | 11.9 |
| 3-Lucentis as Needed | 6.9 |
| 4-Avastin as Needed | 7.7 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | μm (Mean) |
|---|---|
| 1-Lucentis Monthly | 152 |
| 2-Avastin Monthly | 172 |
| 3-Lucentis as Needed | 166 |
| 4-Avastin as Needed | 172 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | μm (Mean) |
|---|---|
| 1-Lucentis Monthly | -100 |
| 2-Avastin Monthly | -79 |
| 3-Lucentis as Needed | -81 |
| 4-Avastin as Needed | -79 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | μm (Mean) |
|---|---|
| 1-Lucentis Monthly | 266 |
| 2-Avastin Monthly | 300 |
| 3-Lucentis as Needed | 294 |
| 4-Avastin as Needed | 308 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | μm (Mean) |
|---|---|
| 1-Lucentis Monthly | -196 |
| 2-Avastin Monthly | -164 |
| 3-Lucentis as Needed | -168 |
| 4-Avastin as Needed | -152 |
"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.~In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity." (NCT00593450)
Timeframe: at 1 Year
| Intervention | No. of Letters (Mean) |
|---|---|
| 1-Lucentis Monthly | 68.8 |
| 2-Avastin Monthly | 68.4 |
| 3-Lucentis as Needed | 68.4 |
| 4-Avastin as Needed | 66.5 |
(NCT00593450)
Timeframe: Baseline and 1 Year
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Increase of ≥15 letters | Increase of 5-14 letters | Change of ≤4 letters | Decrease of 5-14 letters | Decrease of ≥15 letters | |
| 1-Lucentis Monthly | 97 | 90 | 62 | 19 | 16 |
| 2-Avastin Monthly | 83 | 98 | 50 | 18 | 16 |
| 3-Lucentis as Needed | 71 | 103 | 75 | 23 | 13 |
| 4-Avastin as Needed | 76 | 90 | 59 | 23 | 23 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Absent | Present | Data missing | |
| 1-Lucentis Monthly | 167 | 97 | 20 |
| 2-Avastin Monthly | 153 | 100 | 12 |
| 3-Lucentis as Needed | 133 | 137 | 15 |
| 4-Avastin as Needed | 111 | 145 | 15 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Absent | Present | Data missing | |
| 1-Lucentis Monthly | 124 | 151 | 9 |
| 2-Avastin Monthly | 69 | 188 | 8 |
| 3-Lucentis as Needed | 68 | 203 | 14 |
| 4-Avastin as Needed | 52 | 214 | 5 |
(NCT00593450)
Timeframe: at 1 Year
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| 83-97 letters, 20/12-20 | 68-82 letters, 20/25-40 | 53-67 letters, 20/50-80 | 38-52 letters, 20/100-160 | ≤37 letters, ≤20/200 | |
| 1-Lucentis Monthly | 42 | 149 | 52 | 23 | 18 |
| 2-Avastin Monthly | 45 | 134 | 47 | 21 | 18 |
| 3-Lucentis as Needed | 38 | 141 | 66 | 23 | 17 |
| 4-Avastin as Needed | 40 | 127 | 57 | 24 | 23 |
10 reviews available for ticlopidine and Hypertension
| Article | Year |
|---|---|
Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy.
Topics: Angioscopy; Aspirin; Carotid Artery Diseases; Clinical Protocols; Clopidogrel; Drug Therapy, Combina | 2013 |
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Fema | 2011 |
Antiplatelet agents and anticoagulants for hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Clopidogrel; Humans; Hypertension; | 2011 |
A benefit-risk assessment of agents used in the secondary prevention of stroke.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Aspirin; Clinical | 2002 |
[Treatment of acute stroke -- an overview].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Brain Edema; Case-Control Studies; Cereb | 2003 |
Antiplatelet agents and anticoagulants for hypertension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Clopidogrel; Humans; Hypertension; | 2004 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Corona | 2003 |
Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review.
Topics: Angina, Unstable; Angioplasty; Clopidogrel; Coronary Thrombosis; Female; Humans; Hypertension; Middl | 2006 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid | 2006 |
Prevention of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2002 |
10 trials available for ticlopidine and Hypertension
| Article | Year |
|---|---|
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Ka | 2018 |
Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Bevacizumab; Cardiovascul | 2016 |
Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial.
Topics: Aspirin; Blood Pressure; Blood Pressure Determination; Clopidogrel; Drug Therapy, Combination; Femal | 2016 |
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules | 2009 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
The Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Antihypertensive Agents; Aspirin; Clopidogrel; Cognition Disorders; Humans; Hypertension; Magnetic R | 2011 |
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Topics: Age Factors; Aged; Aspirin; Body Weight; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; F | 2012 |
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.
Topics: Aged; Antihypertensive Agents; Aspirin; Black or African American; Blood Pressure; Chi-Square Distri | 2013 |
Randomized controlled trial of symptomatic middle cerebral artery stenosis: endovascular versus medical therapy in a Chinese population.
Topics: Adult; Aged; Angioplasty; Asian People; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combi | 2012 |
The influence of ticlopidine on the natural course of retinal vein occlusion.
Topics: Adenosine Diphosphate; Adult; Aged; Anticoagulants; Clinical Trials as Topic; Diabetes Mellitus; Fem | 1984 |
Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Humans; Hypertension | 1996 |
55 other studies available for ticlopidine and Hypertension
| Article | Year |
|---|---|
Risk factors for gastrointestinal bleeding in patients with cerebral infarction after dual antiplatelet therapy.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; H | 2023 |
The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; DNA Methylation; Drug Resistance; | 2017 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Dec | 2018 |
Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Hyperte | 2014 |
Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.
Topics: Angiotensin II; Animals; Clopidogrel; Fibrosis; Hypertension; Interleukin-1beta; Male; Mice; Mice, I | 2013 |
Pro-inflammatory role of platelets in hypertension-mediated end-organ damage : Editorial to: "Inhibition of Platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis" by L.-X. Jia et al.
Topics: Animals; Clopidogrel; Fibrosis; Hypertension; Male; Myocarditis; Platelet Aggregation Inhibitors; Pu | 2013 |
Acquired pure red cell aplasia due to treatment with clopidogrel: first case report.
Topics: Clopidogrel; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hy | 2014 |
Clopidogrel preserves whole kidney autoregulatory behavior in ANG II-induced hypertension.
Topics: Angiotensin II; Animals; Clopidogrel; Hypertension; Kidney; Male; Purinergic P2Y Receptor Antagonist | 2014 |
Hypertension, platelets, and inflammatory responses.
Topics: Animals; Fibrosis; Hypertension; Male; Myocarditis; Platelet Aggregation Inhibitors; Purinergic P2Y | 2014 |
DTB Select: 3 | March 2014.
Topics: Alzheimer Disease; Antibodies, Monoclonal, Murine-Derived; Automobile Driving; Child; Chronic Pain; | 2014 |
Anti-platelet therapy with clopidogrel prevents endothelial dysfunction and vascular remodeling in aortas from hypertensive rats.
Topics: Adenosine Diphosphate; Animals; Aorta; Blood Pressure; Clopidogrel; Disease Models, Animal; Endothel | 2014 |
Answer to: "Histogram and vertical bar diagram: often misapprehended concept" by M. Lakshmanan.
Topics: Animals; Fibrosis; Hypertension; Male; Myocarditis; Platelet Aggregation Inhibitors; Purinergic P2Y | 2014 |
Histogram and vertical bar diagram: often misapprehended concept.
Topics: Animals; Fibrosis; Hypertension; Male; Myocarditis; Platelet Aggregation Inhibitors; Purinergic P2Y | 2014 |
Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascula | 2015 |
Analysis of periinterventional complications of intracranial angioplasty and stenting: a single center experience.
Topics: Aged; Angioplasty; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Diabetes Complication | 2014 |
J Curve and Cuff Artefact, and Diagnostic Inertia in Resistant Hypertension.
Topics: Aspirin; Blood Pressure; Female; Humans; Hypertension; Male; Secondary Prevention; Stroke, Lacunar; | 2016 |
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
Topics: Aged; Asian People; Case-Control Studies; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CY | 2016 |
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Clopidogrel; Dabigatran | 2016 |
[Cholestatic hepatitis as a ticlopidine-induced complication of treatment - a case report].
Topics: Aged; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Female; Humans; Hypertensio | 2008 |
Transient ischemic attack associated with stenosis of accessory middle cerebral artery: a case report.
Topics: Aphasia; Aspirin; Cerebral Angiography; Clopidogrel; Constriction, Pathologic; Humans; Hypertension; | 2009 |
Clopidogrel for preventing cardiovascular events.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medicine; | 2009 |
Clopidogrel versus low-dose aspirin as risk factors for epistaxis.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Epistaxis; Humans; Hypertension; Myocardial | 2009 |
Spontaneous spinal epidural hematoma: an urgent complication of adding clopidogrel to aspirin therapy.
Topics: Aspirin; Clopidogrel; Coronary Stenosis; Decompression, Surgical; Drug Interactions; Hematoma, Epidu | 2009 |
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cells, Cultured; Cerebrovascular Circulation; Cilostazol; Clopidog | 2010 |
Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats.
Topics: Acetylcholine; Adenosine Diphosphate; Angiotensin II; Animals; Blotting, Western; Clopidogrel; Dose- | 2010 |
Clopidogrel application: beyond coronary artery disease.
Topics: Animals; Clopidogrel; Hypertension; Male; Mesenteric Arteries; Receptors, Purinergic P2; Receptors, | 2010 |
Thirty-day outcome following carotid artery stenting: a 10-year experience from a single center.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiography; Carotid Stenosis; Clopidogrel; Co | 2010 |
Platelet activation in essential hypertension: implications for antiplatelet treatment.
Topics: Antihypertensive Agents; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Humans; Hypertensio | 2010 |
Acute coronary syndrome and severe haemophilia: an unusual association with challenging treatment.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coagulants; Comorbidity; Coronary Angiography; | 2010 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Predictors of neck bleeding after eversion carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel; Drug | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
An unusual case of systolic hypertension associated with ticlopidine treatment.
Topics: Aged, 80 and over; Blood Pressure; Cardiology; Carotid Arteries; Diabetes Complications; Female; Gas | 2012 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight | 2012 |
Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis.
Topics: Adult; Blood Pressure; Erythropoietin; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; | 2002 |
Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
Topics: Adenosine Diphosphate; Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspiri | 2003 |
I'm a 65-year-old man with high blood pressure and a family history of stroke. Which stroke-prevention medication would be better for me--aspirin or clopidogrel (Plavix)?
Topics: Aged; Aspirin; Clopidogrel; Family Health; Humans; Hypertension; Life Style; Male; Platelet Aggregat | 2003 |
Intracranial bleeding associated with clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Clopidogrel; Coronary Stenosis; Human | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
[Drugs induced Parkinsonism: the case of a 77 year old woman].
Topics: Acetaminophen; Adenocarcinoma; Aged; Antineoplastic Agents; Clopidogrel; Female; Humans; Hypertensio | 2006 |
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspirin | 2006 |
Simultaneous, painless, homolateral oculomotor and trochlear nerve palsies in a patient with type 2 diabetes mellitus. Neuropathy or brainstem infarction?
Topics: Aged; Cerebral Infarction; Clopidogrel; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2006 |
Nontraumatic spinal epidural hematoma associated with clopidogrel.
Topics: Aged; Back Pain; Clopidogrel; Female; Hematoma, Epidural, Spinal; Humans; Hypertension; Magnetic Res | 2006 |
Necrotizing gingivitis: a possible oral manifestation of ticlopidine-induced agranulocytosis.
Topics: Agranulocytosis; Biopsy, Needle; Diagnosis, Differential; Female; Follow-Up Studies; Gingivitis, Nec | 2007 |
Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.
Topics: Actins; Adenosine Triphosphate; Angiotensin II; Animals; Arterioles; Blood Pressure; Cell Proliferat | 2008 |
Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biphenyl Compounds; Blood | 2008 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
[Clinical case of the month. Moskowitz syndrome in a patient treated with ticlopidine].
Topics: Female; Fibrinolytic Agents; Humans; Hypertension; Middle Aged; Purpura, Thrombotic Thrombocytopenic | 1996 |
A case of dermatomyositis complicated by thrombotic thrombocytopenic purpura.
Topics: Anti-Inflammatory Agents; Dermatomyositis; Dipyridamole; Dyspnea; Epoprostenol; Fatal Outcome; Fever | 1997 |
[Lymphocytic colitis and ticlopidine].
Topics: Adrenergic alpha-Antagonists; Aged; Captopril; Colitis; Diarrhea; Female; Humans; Hypertension; Isch | 1998 |
Changes in prostacyclin, thromboxane A2 and F2-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia.
Topics: Aspirin; Dinoprost; Dipyridamole; Eicosapentaenoic Acid; Epoprostenol; Humans; Hyperlipidemias; Hype | 1999 |
Sex differences and similarities in the management and outcome of stroke patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity; | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human | 2000 |
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Com | 2001 |